Mode
Text Size
Log in / Sign up
N/A N=89 Other

Clinical Validation for SpO2 Function of Masimo INVSENSOR00069

Healthy

Enrolled (actual)
89
Serious AEs
0.0%
Results posted
Nov 2024
Primary outcome: Primary: SpO2 Accuracy of Masimo INVSENSOR00069 — 1.72 % of oxygen saturated hemoglobin

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
INVSENSOR00069 (Device)
Age
Adult · 18+ yrs
Sex
All
Sponsor
Masimo Corporation
Primary completion
Dec 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
SpO2 Accuracy of Masimo INVSENSOR00069
1.72

Summary

Assess the accuracy of INVSENSOR00069's peripheral oxygen saturation (SpO2) against contemporaneous measurement from arterial blood gas (ABG) analysis.

Eligibility Criteria

Inclusion Criteria

Influenced by study design:

  • Subject is 18 to 50 years of age.
  • Subject weighs a minimum of 110 lbs.
  • Hemoglobin value ≥ 11 g/dL.
  • Baseline heart rate ≥ 45 bpm and ≤ 90 bpm.
  • Systolic blood pressure ≤ 140 mmHg and ≥ 90 mmHg and diastolic blood pressure ≤ 90 mmHg and ≥ 50 mmHg. If systolic blood pressure is lower than 100 mmHg and/or diastolic blood pressure is lower than 60 mmHg, subject passes an orthostatic blood pressure test.
  • CO value ≤ 3.0% FCOHb.
  • Subject is comfortable to read and communicate in English*. *This is to ensure the subject can provide informed consent (as study materials are currently available in English only) and can comply with study procedures.

Exclusion Criteria

Influenced by device warning labels:

  • Subjects with a skin condition affecting the digits, where the sensor is applied, which would interfere with the path of light (e.g., psoriasis, vitiligo, eczema, angioma, scar tissue, burn, fungal infection, substantial skin breakdown, etc.).
  • Subjects with nail polish or acrylic nails on the digits where sensor needs to be applied, who opt not to remove them.
  • Subject has hemoglobinopathies or synthesis disorders (e.g., thalassemia, sickle cell disease).
  • Subject has a peripheral vascular or vasospastic disease (e.g., Raynaud's disease).

Influenced by study design/environment:

  • Subjects who do not pass the health assessment for safe participation in the study procedures.
  • Difficulty inserting an intravenous line in the subject's hand or arm and/or an arterial line in the radial artery of the subject's wrist.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT06120777). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search